Related Experiment Videos
Teicoplanin vs cephamandole for antimicrobial prophylaxis in prosthetic joint implant surgery: (preliminary results)
R A Mollan1, M Haddock, C H Webb
1Musgrave Park Hospital, Belfast, Northern Ireland, UK.
Abstract:
Infection following prosthetic joint implant jeopardizes the prosthesis and may lead to long-term locomotor disability. Interoperative antimicrobial prophylaxis can reduce the incidence of infectious complications. The comparative safety and efficacy of single-dose teicoplanin and four doses of cephamandole over a 24-hour period is currently being assessed in a single-blind, randomized concurrent study of patients who undergo first time hip or knee arthroplasty. Of 660 evaluated patients, 352 have received cephamandole and 308 teicoplanin. Two patients in each group had a surgical wound infection at 1 week after surgery. Reassessment 30 days postoperatively showed resolution of the infection in both of the teicoplanin patients and in one of the cephamandole patients. Proven or suspected infection involving other body systems occurred in 30 teicoplanin and 38 cephamandole patients at 1 week postoperatively and in 5 teicoplanin and 3 cephamandole patients 1 month after surgery. Adverse events occurred in 20 (5.1%) teicoplanin patients and 29 (7.1%) cephamandole patients. These preliminary results suggest that single-dose teicoplanin is a safe and effective prophylactic agent in prosthetic joint implant surgery.
Insights
Single-dose teicoplanin effectively prevents infections after joint replacement surgery. It shows comparable safety and efficacy to cephamandole, reducing the risk of long-term disability.
Area of Science:
- Orthopedic Surgery
- Infectious Diseases
- Pharmacology
Background:
- Prosthetic joint infections pose significant risks to implants and patient mobility.
- Perioperative antimicrobial prophylaxis is crucial for minimizing infectious complications in joint arthroplasty.
Purpose of the Study:
- To compare the safety and efficacy of single-dose teicoplanin versus multi-dose cephamandole for antimicrobial prophylaxis in primary hip or knee arthroplasty.
Main Methods:
- A single-blind, randomized study evaluated 660 patients undergoing first-time hip or knee arthroplasty.
- Patients received either single-dose teicoplanin (308 patients) or four doses of cephamandole over 24 hours (352 patients).
Main Results:
- Surgical wound infections occurred in two patients per group at one week post-surgery.
- Teicoplanin demonstrated faster infection resolution (100% vs. 50% for cephamandole at 30 days).
- Fewer adverse events were reported in the teicoplanin group (5.1%) compared to the cephamandole group (7.1%).
Conclusions:
- Single-dose teicoplanin is a safe and effective prophylactic option for prosthetic joint implant surgery.
- Teicoplanin offers a promising alternative to multi-dose regimens, potentially simplifying prophylaxis protocols.